Newsroom Spotlight Story UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS) Read more Press Releases UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership… Read More UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant… Read More UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S.… Read More Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award Read More Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients… Read More UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S. Read More UCB Stories Inside a PowerHouSe: Conversations, Connection & Learning at the 2026 UCB HS Summit Read More UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI®… Read More Supporting Families During Dravet Syndrome Awareness Month: A look into Camp Small Steps Read More Running Toward Relief: How Cassie is Reclaiming Her Life With Psoriatic Arthritis Read More UCB Issues Voluntary Recall of Select Lots of CIMZIA® Pre-Filled Syringes (PFS) in the United States Read More UCB’s Catherine Rives and Alexandria Harrold Recognized by Healthcare Businesswomen’s Association… Read More View all Subscribe For More Information Media Contact Speaker Requests Connect with Us on Social @UCBUSA Instagram @UCBUSA X (formerly Twitter) UCB LinkedIn UCB Facebook UCB USA YouTube UCB IN THE U.S. U.S. Leadership PATIENTS
Spotlight Story UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA® (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS) Read more